Journal of Diabetes Mellitus

Journal of Diabetes Mellitus

ISSN Print: 2160-5831
ISSN Online: 2160-5858
www.scirp.org/journal/jdm
E-mail: jdm@scirp.org
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] Efficacy and Safety of 1: 1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes …
2020
[2] Diabetes Care Publish Ahead of Print, published online April 15, 2020
2020
[3] Fixed‐ratio combination of basal insulin and glucagon‐like peptide‐1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative …
2020
[4] Benefits of the fixed‐ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time‐to …
2020
[5] Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing …
2020
[6] A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese …
2020
[7] Neuroprotective Effects of Casein-Derived Peptide Met-Lys-Pro (MKP) in a Hypertensive Model
2020
[8] Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study)
2020
[9] Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
2019
[10] Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub …
Diabetology International, 2016
[11] Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered …
Diabetology International, 2016
[12] Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan
Diabetology International, 2016
[13] Improved treatment satisfaction and self-reported health status after introduction of basal-supported oral therapy using insulin glargine in patients with type 2 …
Diabetes Therapy, 2015
[14] Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study
Diabetes Therapy, 2015
[15] Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan
Diabetology International, 2015
Free SCIRP Newsletters
Add your e-mail address to receive free newsletters from SCIRP.
Copyright © 2006-2021 Scientific Research Publishing Inc. All Rights Reserved.
Top